These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18588997)

  • 1. Drug development and IBS drugs: experience from the past, current challenges, and proposal for the future.
    Camilleri M
    Curr Opin Pharmacol; 2008 Dec; 8(6):671-6. PubMed ID: 18588997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.
    Camilleri M; Chang L
    Gastroenterology; 2008 Dec; 135(6):1877-91. PubMed ID: 18848833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.
    Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D
    Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists.
    Mangel AW; Fehnel SE
    Neurogastroenterol Motil; 2008 Oct; 20(10):1086-93. PubMed ID: 18826559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
    Corsetti M; Tack J
    Neurogastroenterol Motil; 2013 Jun; 25(6):453-7. PubMed ID: 23672677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personal view: adequate relief as a primary endpoint in irritable bowel syndrome.
    Mangel AW
    Aliment Pharmacol Ther; 2006 Apr; 23(7):879-81. PubMed ID: 16573790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational agents for the irritable bowel syndrome.
    Ghaith O; El-Halabi M; Hashash JG; Sharara AI
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1161-78. PubMed ID: 20836617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK; Ainsworth MA
    Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. End points in irritable bowel syndrome.
    Mangel AW; Fehnel SE
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
    Dobrek Ł; Thor PJ
    Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome.
    Drossman DA; Danilewitz M; Naesdal J; Hwang C; Adler J; Silberg DG
    Am J Gastroenterol; 2008 Oct; 103(10):2562-9. PubMed ID: 18775020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonergic agents and the irritable bowel syndrome: what goes wrong?
    Spiller R
    Curr Opin Pharmacol; 2008 Dec; 8(6):709-14. PubMed ID: 18672092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of functional bowel disorders: any light at the end of the tunnel?
    Boeckxstaens GE
    Curr Opin Pharmacol; 2008 Dec; 8(6):669-70. PubMed ID: 18835367
    [No Abstract]   [Full Text] [Related]  

  • 14. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
    Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FDA and IBS drug development.
    Mangel AW
    Am J Gastroenterol; 2009 Dec; 104(12):3106; author reply 3106. PubMed ID: 19956135
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints.
    Camilleri M; Mangel AW; Fehnel SE; Drossman DA; Mayer EA; Talley NJ
    Clin Gastroenterol Hepatol; 2007 May; 5(5):534-40. PubMed ID: 17428741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA's decision-making process: isn't it time to temper the principle of protective paternalism?
    Brandt LJ
    Am J Gastroenterol; 2008 May; 103(5):1226-7. PubMed ID: 18477347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study.
    Brennan BP; Fogarty KV; Roberts JL; Reynolds KA; Pope HG; Hudson JI
    Hum Psychopharmacol; 2009 Jul; 24(5):423-8. PubMed ID: 19548294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.
    Evangelista S
    Curr Opin Investig Drugs; 2007 May; 8(5):416-22. PubMed ID: 17520871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegaserod in patients with irritable bowel syndrome.
    Schooff M; Stelter C
    Am Fam Physician; 2004 Dec; 70(11):2107-8. PubMed ID: 15606056
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.